Erlotinib plus Onartuzumab in advanced non-small cell lung cancer: METLung study stopped on lack of clinically efficacy
Roche has announced that an independent data monitoring Committee has recommended that the phase III METLung study be stopped due to a lack of clinically meaningful efficacy.
The study evaluated if ...
read article